PCSK9, C-Terminal Avi-His, Biotin-Labeled Recombinant

PCSK9 (proprotein convertase subtilisin/kexin type 9), also known as FH3, HCHOLA3, and PC9, belongs to the proprotein convertase family of protein and is a crucial player in the regulation of plasma cholesterol homeostasis. It is synthetized in an inactive form, which is converted into the mature active form by proprotein convertases. It binds to the ectodomain of the following hepatic low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low-density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2) and promotes their degradation. PCSK9 acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway, targeting the complex to the lysosomes. PSCK9 inhibition allows LDLR to be recycled, and further cycles of LDL removal from circulation. The use inhibitors targeting PSCK9 have been approved by the FDA since 2015, such as the monoclonal antibody evolocumab. Further studies and drug development will bring into light the importance of this protein in lipoprotein homeostasis.

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation confirmed to be ≥90%.For more information on enzymatic biotinylation, please see ourTech Note.